Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies
M. Lebwohl
Mount Sinai School of Medicine, New York, NY, U.S.A.
Search for more papers by this authorP. Szapary
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorC. Guzzo
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorN. Yeilding
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorS. Li
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorM-C. Hsu
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorC.E.M. Griffiths
Dermatology Centre, Salford Royal Hospital University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.
Search for more papers by this authorM. Lebwohl
Mount Sinai School of Medicine, New York, NY, U.S.A.
Search for more papers by this authorP. Szapary
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorC. Guzzo
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorN. Yeilding
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorS. Li
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorM-C. Hsu
Centocor Research & Development, Inc., Malvern, PA, U.S.A.
Search for more papers by this authorC.E.M. Griffiths
Dermatology Centre, Salford Royal Hospital University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K.
Search for more papers by this authorFunding sourcesThe studies upon which the analyses for this report were based were supported by Centocor Research and Development, Inc., Malvern, PA, U.S.A.
Conflicts of interestConflicts of interest statements are listed for each author in Appendix 1.
Summary
Background Patients with psoriasis are believed to be at an increased risk of cardiovascular (CV) morbidity, and the effect of biological agents on CV safety is not fully understood.
Objectives To evaluate the effect of ustekinumab on CV events using detailed analyses of pooled data from the phase II/III clinical studies of its use in moderate to severe psoriasis.
Methods The incidence of major adverse CV events [MACE: myocardial infarction (MI), stroke or CV death] is reported. Meta-analyses using risk difference and odds ratio estimates are presented based on data collected during the placebo-controlled period of ustekinumab trials. The cumulative numbers of events and rates of MIs and strokes over time were compared with those expected in the psoriasis and/or general populations.
Results During the placebo-controlled period (12/20 weeks), five MACE were reported in 1582 ustekinumab-treated patients [0·3%; 95% confidence interval (CI) 0·1–0·7%] compared with no events in 732 placebo-treated patients (0·0%; 95% CI 0·0–0·5%). MACE rates were stable over time during both the controlled and uncontrolled study periods, with 19 of 3117 ustekinumab-treated patients (0·6%) experiencing 21 events for a combined event rate per 100 patient-years of follow-up of 0·44 (95% CI 0·27–0·67) through up to 3 years. Standardized incidence ratios for comparison of ustekinumab clinical data with external data sources ranged from 0·34 to 0·52, suggesting no increased risk of MI or stroke in ustekinumab-treated patients compared with the general U.S. and psoriasis populations.
Conclusions The totality of available clinical data suggests neither a detrimental nor a beneficial effect of ustekinumab on serious CV events. Additional data are needed to define the net effect of ustekinumab on CV events.
References
- 1 Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899–912.
- 2 Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–71.
- 3 Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485–96.
- 4 Weiss SC, Kimball AB, Liewehr DJ et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47: 512–18.
- 5 Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280–4.
- 6 Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008; 21: 54–9.
- 7 Kimball AB, Jacobson C, Weiss S et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383–92.
- 8 Fortune DG, Main CJ, O’Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137: 755–60.
- 9 Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005; 53: 573–7.
- 10 Shbeeb M, Uramoto KM, Gibson LE et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982–1991. J Rheumatol 2000; 27: 1247–50.
- 11 Kimball AB, Gladman D, Gelfand JM et al. National Psoriasis Foundation. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58: 1031–42.
- 12 Gladman DD, Antoni C, Mease P et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl. II): ii14–17.
- 13 Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–35.
- 14 Kimball AB, Wu Y. Cardiovascular disease and classic cardiovascular risk factors in patients with psoriasis. Int J Dermatol 2009; 48: 1147–56.
- 15 Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007; 57: 347–54.
- 16 Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–41.
- 17 Gelfand JM, Dommasch ED, Shin DB et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009; 129: 2411–18.
- 18 Mehta NN, Azfar RS, Shin DB et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010; 31: 1000–6.
- 19 Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493–9.
- 20 Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. J Eur Acad Dermatol Venereol 2010; 24: 885–92.
- 21 Wakkee M, Herings RMC, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 2010; 130: 962–7.
- 22 Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther 2009; 22: 431–40.
- 23 Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160: 810–20.
- 24 Davidovici BB, Sattar N, Jorg PC et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785–96.
- 25 Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284–9.
- 26 Krueger GG, Langley RG, Leonardi C et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580–92.
- 27 Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–74.
- 28 Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675–84.
- 29 Griffiths CE, Strober BE, van de Kerkhof P et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118–28.
- 30 Segal BM, Constantinescu CS, Raychaudhuri A et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7: 796–804.
- 31 Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology 2008; 135: 1130–41.
- 32 Gottlieb AG, Menter A, Mendelsohn A et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373: 633–40.
- 33 Tian L, Cai T, Pfeffer MA et al. Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 × 2 tables with all available data but without data artificial continuity correction. Biostatistics 2009; 10: 275–81.
- 34 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004; 23: 1351–75.
- 35 Framingham SNP Health Association Resource. Study Accession: phs000007.v11.p5. Available at: http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v11.p5 (last accessed 15 February 2011).
- 36 GPRD. General Practice Research Database. Available at: http://www.gprd.com/products/database.asp (last accessed 15 February 2011).
- 37 Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46–215.
- 38 Wakkee M, Thio HB, Prens EP et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007; 190: 1–9.
- 39 Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–95.
- 40 Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515–81.
- 41 Gori AM, Cesari F, Marcucci R et al. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis 2009; 202: 255–62.
- 42 Mangino M, Braund P, Singh R et al. Association analysis of IL-12B and IL-23R polymorphisms in myocardial infarction. J Mol Med 2008; 86: 99–103.
- 43 Prodanowich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262–7.
- 44 Choi HK, Hernán MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173–7.
- 45 Dixon WG, Symmons DPM. What effects might anti-TNFα treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFα in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 1132–6.
- 46 Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130–8.
- 47 Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117–25.
- 48 Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999; 19: 734–42.
- 49 Hauer AD, Uyttenhove C, de Vos P et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005; 112: 1054–62.
- 50 Gordon K, Langley R, Gottlieb A et al. Efficacy and safety results from a phase III, randomized controlled trial comparing two dosing regimens of ABT-874 to placebo in patients with moderate to severe psoriasis (P068). J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 4): 30 (Abstract).
- 51 Strober B, Crowley J, Yamauchi P et al. ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: efficacy and safety results (P023). J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 4): 10 (Abstract).
- 52 Menter A, Gottlieb A, Leonardi C et al. Efficacy and safety of ABT-874 vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis (P071). J Eur Acad Dermatol Venereol 2010; 24 (Suppl 4): 31–2 (Abstract).
- 53 Reich K, Langley R, Papp K et al. Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis (P555). Presented at the 19th Congress of the European Academy of Dermatology and Venereology, 6–10 October 2010, Gothenburg, Sweden.
- 54 Kimball AB, Gordon KB, Langley RG et al. Safety and efficacy of ABT-874, a fully human interleukin-12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Arch Dermatol 2008; 144: 200–7.
